influenza
acut
respiratori
infect
ari
common
human
diseas
nearli
infecti
diseas
popul
suffer
one
infect
least
year
current
epidem
process
character
simultan
circul
differ
type
influenza
virus
annual
outbreak
respiratori
virus
winter
spring
season
howev
parainfluenza
preval
throughout
year
ari
caus
viral
bacteri
pathogen
result
hospit
death
particularli
among
young
children
older
adult
highrisk
group
virus
lead
caus
acut
respiratori
diseas
throughout
world
common
viral
etiolog
agent
ari
respiratori
syncyti
viru
rsv
human
metapneumoviru
mpv
influenza
b
virus
parainfluenza
virus
piv
adenovirus
adv
human
rhinovirus
rv
human
coronavirus
cov
enterovirus
env
human
bocaviru
bov
addit
human
polyomavirus
ki
wu
detect
patient
respiratori
infect
although
ari
tradit
thought
caus
singl
virus
increas
number
report
report
respiratori
diseas
occur
dual
multipl
viru
infect
suggest
respiratori
viral
coinfect
affect
diseas
sever
studi
suggest
dual
multipl
infect
increas
sever
respiratori
diseas
dual
multipl
infect
may
actual
protect
human
piv
type
common
human
respiratori
tract
pathogen
caus
ari
pneumonia
bronchiol
known
import
communityacquir
pneumonia
pathogen
transplant
recipi
immunosuppress
patient
also
import
pathogen
immunocompet
adult
normal
adult
host
clinic
present
piv
pneumonia
may
clinic
close
mimic
pneumonia
current
approv
vaccin
prevent
respiratori
viral
infect
despit
continu
effort
field
medic
cover
almost
possibl
respons
infecti
process
often
show
desir
result
idea
fast
elimin
viral
agent
cell
infect
bodi
still
topic
issu
emerg
drugresist
influenza
variant
led
declin
efficaci
drug
oseltamivir
tamiflu
amantadin
symmetrel
rimantadin
flumadin
therefor
new
therapeut
respiratori
viral
infect
novel
mechan
action
new
target
urgent
requir
moreov
coinfect
influenza
respiratori
virus
decreas
effici
aforement
drug
establish
oligoribonucleotidesdmannitol
ornsdm
complex
total
yeast
rna
modifi
dmannitol
possess
antivir
antiinflammatori
immunomodulatori
effect
complex
regist
commerci
name
nuclex
ukrain
medicin
effect
influenza
viru
surfac
antigen
depress
viru
activ
increas
interferon
product
infect
influenza
viru
afort
adapt
vitro
ornsdm
antivir
drug
prove
effect
fight
mani
infecti
diseas
previous
use
patient
suffer
influenza
ari
studi
perform
determin
antivir
effici
ornsdm
drug
differ
strain
influenza
virus
clinic
effici
ornsdm
patient
ari
variou
etiolog
ornsdmannitol
ornsdm
yeast
rna
modifi
dmannitol
dm
ornsdm
purchas
subsidiari
compani
biosel
kyiv
ukrain
influenza
viru
avian
influenza
viru
obtain
nation
viru
collect
di
ivanovski
institut
virolog
russian
academi
medic
scienc
ram
moscow
russia
human
epitheli
type
canin
kidney
mdck
cell
obtain
russian
cell
cultur
collect
ram
cell
cultur
plate
monolay
state
mem
medium
ad
fetal
bovin
serum
fb
cell
growth
cultur
viru
onehundr
eight
patient
young
middl
age
influenza
other
ari
observ
clinic
infecti
diseas
ya
horbachevski
ternopil
state
medic
univers
procedur
perform
studi
involv
human
particip
accord
ethic
standard
institut
andor
nation
research
committe
helsinki
declar
later
amend
compar
ethic
standard
form
inject
capsul
ornsdm
concentr
mgml
studi
make
capsul
form
ornsdm
dissolv
mem
medium
inject
ornsdm
dissolv
mem
medium
contain
mgml
arginin
ornsdm
capsul
inject
form
concentr
ornsdm
cell
infect
well
plate
monolay
cell
ad
viru
hour
incub
mem
medium
appropri
ornsdm
concentr
ad
well
infect
cell
medium
incub
h
level
destruct
chang
detect
light
microscop
control
infect
cell
viru
without
drug
form
experi
perform
three
time
medium
remov
experiment
control
well
cell
wash
withphosphatebuff
salin
pb
ad
solut
guinea
pig
red
blood
cell
gprbc
determin
degre
hemagglutinin
ha
activ
use
hemadsorpt
assay
plate
cell
gprbc
incub
min
incub
cell
wash
pb
twice
hemadsorpt
cell
observ
light
microscop
quantifi
hemadsorpt
activ
determin
averag
number
gprbc
adsorb
per
ten
cell
analysi
least
cell
per
replic
cultur
remov
medium
dilut
dilut
medium
ad
plate
monolay
cell
eight
well
infect
one
dilut
incub
h
infect
determin
hemadsorpt
assay
infecti
titer
express
number
decim
logarithm
highest
dilut
factor
produc
cell
hemadsorpt
activ
read
compound
appropri
concentr
dissolv
mem
trypsin
incub
mdck
cell
h
concentr
compound
test
triplic
cell
cultur
wash
twice
pb
incub
appropri
virus
moi
h
monolay
wash
twice
pb
compoundcontain
medium
ad
plate
incub
h
presenc
viru
titer
supernat
determin
assay
cultiv
viru
mdck
cell
h
presenc
detect
viru
cultur
medium
ml
transfer
correspond
well
roundbottom
plate
mix
ml
chicken
erythrocyt
result
check
h
incub
room
temperatur
inhibit
concentr
select
index
si
ratio
compound
calcul
data
obtain
rimantadin
use
refer
compound
studi
antineuraminidas
activ
compound
conduct
measur
activ
neuraminidas
reaction
fluorogen
substrat
inject
capsul
form
made
analysi
ornsdm
antivir
activ
form
ornsdm
concentr
viru
dilut
assay
buffer
mm
me
buffer
ph
mm
mix
plate
plate
ornsdm
viru
incub
min
mm
substrat
solut
acid
ad
well
plate
incub
min
room
temperatur
reaction
stop
stop
solut
ethanol
glycin
ph
follow
measur
luminesc
multifunct
plate
reader
victor
ex
nm
em
nm
base
data
obtain
inhibit
concentr
compound
calcul
viru
oseltamivir
carboxyl
threefold
dilut
nm
use
refer
compound
determin
etiolog
patient
ari
nasal
oropharynx
swab
evalu
polymeras
chain
reaction
pcr
use
rotorgen
amplisen
test
system
regist
ukrain
patient
divid
two
group
first
group
main
group
consist
individu
took
ornsdm
complex
therapi
second
group
control
group
patient
receiv
standard
treatment
arbidol
etiotrop
drug
group
form
random
basi
chosen
accord
age
sex
etiolog
diseas
epidemiolog
criteria
clinic
sign
diseas
criteria
patient
inclus
studi
patient
influenza
ari
year
old
sex
exclus
criteria
children
adult
year
old
presenc
sever
concomit
diseas
could
affect
cours
diseas
burden
allerg
histori
mild
ill
requir
hospit
determin
sever
diseas
degre
increas
bodi
temperatur
durat
sever
durat
intox
syndrom
gener
weak
headach
myalgia
bodi
ach
nausea
vomit
catarrh
syndrom
throat
irrit
hoars
voic
cold
cough
identifi
respons
doctor
increas
bodi
temperatur
day
clinic
evid
intox
catarrh
manifest
point
averag
sever
diseas
convers
sharp
increas
bodi
temperatur
clinic
evid
intox
sever
myalgia
signific
gener
weak
develop
pneumonia
point
sever
diseas
patient
clinic
sampl
collect
pcr
assay
begin
hospit
period
earli
reconvalesc
day
ill
mg
ornsdm
administ
four
time
day
ingest
meal
day
treatment
effect
determin
due
clinic
data
result
pcr
statist
analysi
perform
statistica
softwar
packag
data
present
mean
twoway
analysi
student
ttest
spearman
rank
correl
analys
wilcoxon
signedrank
test
use
p
consid
signific
studi
fragment
integr
research
work
improv
diagnost
medic
prevent
measur
widespread
viral
parasit
diseas
state
registr
number
depart
infecti
diseas
epidemiolog
dermatolog
venereolog
ya
horbachevski
ternopil
state
medic
univers
ministri
healthcar
ukrain
mh
ukrain
approv
expert
problemat
commiss
mh
nation
academi
medic
scienc
nam
ukrain
infecti
parasit
diseas
june
protocol
bioethic
commiss
ya
horbachevski
ternopil
state
medic
univers
detect
moral
ethic
norm
violat
studi
protocol
ornsdm
medicin
regist
ukrain
introduc
clinic
practic
singleblind
studi
decre
mh
ukrain
two
year
begin
studi
studi
includ
comparison
clinic
virolog
activ
ornsdm
arbidol
arbidol
approv
clinic
use
registr
number
antivir
effect
ornsdm
capsul
inject
form
vitro
determin
abil
inhibit
hemadsorpt
activ
cell
infect
infect
percentag
hemadsorpt
cell
h
incub
inject
form
ornsdm
concentr
mgml
concentr
inject
form
decreas
mgml
number
cell
absorb
red
blood
cell
howev
inject
form
drug
also
inhibit
number
hemadsorbt
cell
figur
capsul
form
ornsdm
also
significantli
reduc
hemadsorbt
abil
infect
cell
concentr
mgml
ornsdm
capsul
form
percentag
hemadsorbt
cell
rang
respect
wherea
hemadsorpt
activ
cell
reduc
respect
incub
drug
concentr
mgml
h
incub
infect
cell
form
ornsdm
concentr
mgml
infect
inhibit
mgml
ornsdm
inject
form
reduc
infecti
titer
compar
control
mgml
ornsdm
capsul
form
decreas
infecti
titer
convers
infecti
titer
incub
viru
mgml
inject
form
mgml
capsul
insignificantli
remain
unchang
incub
viru
mgml
form
comparison
control
also
import
studi
antivir
effect
ornsdm
influenza
viru
strain
especi
pandem
influenza
aiv
effect
ornsdm
differ
concentr
infect
pandem
influenza
aiv
prove
drug
inhibit
infect
virus
cell
figur
effect
dose
drug
pandem
viru
mgml
select
index
accept
concentr
mgml
concentr
mgml
inhibit
viru
strain
less
effect
oneandahalf
logarithm
drug
concentr
decreas
mgml
effect
remain
within
one
logarithm
drug
concentr
less
mgml
antiinfluenza
effect
result
research
also
demonstr
ornsdm
concentr
mgml
activ
aiv
select
index
inhibit
na
activ
influenza
viru
ornsdm
form
studi
figur
rate
na
activ
viru
affect
ornsdm
inject
form
concentr
reach
concentr
enzym
activ
lower
concentr
drug
inject
form
almost
effect
drug
capsul
form
less
effect
na
activ
influenza
specifi
concentr
drug
posit
effect
concentr
rate
na
action
sever
cours
diseas
observ
patient
main
group
patient
control
one
moder
cours
patient
main
group
patient
control
group
without
signific
differ
group
p
pneumonia
complic
diagnos
patient
patient
main
group
control
one
p
group
patient
gender
age
p
main
diseas
sign
patient
group
fever
intox
catarrh
syndrom
identifi
sever
diseas
examin
patient
pcr
stay
hospit
first
three
day
ill
show
posit
result
patient
group
six
patient
posit
result
group
variou
combin
virus
reveal
two
pathogen
simultan
doubl
infect
group
patient
examin
diseas
etiolog
differ
significantli
p
complex
treatment
ornsdm
main
group
patient
posit
effect
cours
diseas
acceler
patient
recoveri
drug
contribut
signific
decreas
durat
febril
period
last
averag
day
main
group
day
control
group
p
increas
bodi
temperatur
observ
first
two
day
patient
main
group
longer
person
wherea
control
group
shortterm
day
hyperthermia
record
patient
last
three
day
longer
p
depend
etiolog
factor
influenc
durat
febril
period
within
adapt
treatment
establish
cough
last
twothre
day
patient
main
group
number
person
cough
much
lower
control
group
p
durat
cough
six
day
longer
patient
main
group
significantli
lower
p
compar
control
one
averag
group
treat
ornsdm
cough
last
day
day
control
group
patient
p
treatment
ornsdm
examin
patient
contribut
regress
diseas
clinic
manifest
normal
number
laboratori
find
well
depend
main
symptom
durat
diseas
sever
patient
receiv
differ
treatment
defin
tabl
durat
intox
catarrh
syndrom
hospit
stay
patient
main
group
moder
ari
sever
shorter
sever
cours
diseas
p
correl
patient
control
group
statist
signific
effect
ornsdm
reduc
main
clinic
symptom
time
need
inpati
treatment
denot
moder
sever
cours
group
p
tabl
influenc
differ
treatment
durat
diseas
main
manifest
studi
depend
pneumonia
presenc
patient
data
present
tabl
show
fever
intox
durat
consider
shorter
ornsdmtreat
patient
group
patient
ari
uncompl
complic
pneumonia
p
durat
cough
main
group
day
day
control
group
p
patient
receiv
ornsdm
clinic
sign
last
longer
stay
longer
hospit
viru
elimin
depend
differ
treatment
method
studi
etiolog
peopl
main
group
deciph
admiss
accord
pcr
posit
result
earli
convalesc
pathogen
found
patient
main
group
patient
control
group
p
case
polyinfect
result
pcr
earli
convalesc
neg
main
group
influenza
viru
erad
reach
posit
case
control
group
viru
detect
patient
p
erad
rsv
evidenc
patient
detect
main
group
patient
control
group
detect
p
erad
adv
found
patient
main
group
three
five
two
detect
control
group
piv
observ
two
eight
patient
main
group
four
seven
patient
control
group
p
therefor
due
pcr
viru
found
rare
patient
treat
ornsdm
p
tabl
oligoribonucleotidesdmannitol
ornsdm
complex
total
yeast
rna
modifi
dmannitol
dm
wide
rang
biolog
activ
use
antivir
treatment
play
key
role
antivir
activ
viral
pathogen
common
etiolog
agent
ari
present
studi
ornsdm
evalu
abil
inhibit
pandem
influenza
influenza
viru
vitro
studi
ornsdm
antivir
effect
vitro
prove
form
drug
inhibit
viru
infect
inject
form
ornsdm
stronger
effect
capsul
form
degre
antivir
effect
form
depend
concentr
drug
analys
avail
avian
influenza
virus
circul
worldwid
suggest
virus
suscept
oseltamivir
peramivir
zanamivir
howev
evid
antivir
resist
report
hpai
asian
lineag
aiv
cdcgovfluavianflupreventionhtm
therefor
import
search
influenza
antivir
drug
wide
spectrum
antivir
action
result
research
figur
prove
ornsdm
concentr
mgml
activ
aiv
select
index
obtain
result
suggest
ornsdm
probabl
use
antivir
drug
aiv
whilst
found
ornsdm
antivir
activ
pandem
viru
figur
influenza
viru
two
surfac
respons
adsorpt
penetr
releas
viru
cell
previous
prove
ornsdm
specif
antivir
effect
due
abil
inhibit
na
action
influenza
viru
vitro
comparison
result
previou
research
na
action
influenza
viru
prove
effect
inhibit
receptor
studi
inhibit
na
activ
strain
inject
form
ornsdm
take
place
concentr
figur
time
less
research
influenza
viru
result
suggest
greater
effici
inject
form
well
differ
sensit
differ
strain
na
inhibit
effect
ornsdm
result
also
suggest
antivir
activ
ornsdm
influenza
aiv
vitro
antivir
activ
ornsdm
attribut
inhibit
na
activ
interact
influenza
virus
inhibit
tolllik
receptor
impair
upregul
gene
induc
virus
previou
studi
found
ornsdm
clinic
effect
treat
patient
chronic
hepat
c
diabet
type
studi
clinic
data
show
comprehens
treatment
influenza
viru
piv
rsv
adv
infect
ari
unidentifi
ornsdm
improv
diseas
clinic
find
significantli
decreas
durat
fever
intox
syndrom
cough
hospit
stay
durat
patient
moder
sever
form
diseas
treatment
ornsdm
caus
erad
influenza
viru
advvirus
patient
influenza
ari
experiment
clinic
result
show
ornsdm
antivir
activ
wide
rang
spectrum
respiratori
virus
result
obtain
indic
ornsdm
use
treatment
coinfect
influenza
respiratori
virus
inject
dosag
form
ornsdm
stronger
antivir
effect
compar
capsul
form
futur
research
preclin
aiv
influenza
clinic
effici
ornsdm
inject
form
studi
